Tucatinib Combination Therapy Shows Remarkable Success in Metastatic Esophageal Cancer Patient
Key Insights
An 83-year-old patient with stage IV esophageal cancer (search) has survived over four years on a clinical trial combining tucatinib with standard chemotherapy (search) and Herceptin at the University of Colorado Cancer Center.
The treatment regimen caused the patient's metastatic disease to disappear after just a few treatments, leaving only the primary esophageal tumor which has remained stable.
This represents a significant improvement over the average 1.5-year survival for metastatic esophageal cancer (search) patients receiving standard care at the time.
An 83-year-old patient with metastatic esophageal cancer (search) has achieved remarkable survival outcomes through a clinical trial at the University of Colorado Cancer Center, demonstrating the potential of combining tucatinib with standard-of-care therapy for HER2 (search)-positive esophageal cancers.
Norm Krimbill was diagnosed with stage IV esophageal cancer (search) in April 2021 after experiencing difficulty swallowing. An endoscopy revealed a tumor at the junction of the esophagus and stomach, while a PET scan showed the cancer had metastasized to lymph nodes, spine, and ribs. With surgery and radiation ruled out due to extensive disease spread, Krimbill enrolled in a clinical trial led by Dr. Sunnie Kim examining the addition of oral tucatinib to standard treatment.
Novel Combination Approach
The trial protocol combines tucatinib with chemotherapy (search) plus Herceptin (trastuzumab), a targeted therapy that blocks HER2 (search) protein activity. According to Dr. Alexis Leal, the medical oncologist overseeing Krimbill's treatment, this dual-targeting approach addresses HER2-positive cancers (search)' uncontrolled cell proliferation through complementary mechanisms.
"Herceptin binds to the receptor on the outside of the cell, and tucatinib works on the receptor on the inside of the cell, so they impact the receptor in different ways to create a more complete response," Leal explained.
Exceptional Treatment Response
After just a few treatments, Krimbill's metastatic disease disappeared, leaving only the primary esophageal tumor. While the cancer will never be fully cured, it has remained stable without growth since treatment initiation. This outcome represents a dramatic improvement over historical expectations.
"The average lifespan of someone with metastatic disease with standard care, if you look at the data, was around a year-and-a-half at that time," Leal noted. "He started with us in April of 2021, and here we are in 2026, and he still is on the first-line treatment."
Quality of Life Maintenance
Krimbill has received 115 infusions over four years while maintaining excellent quality of life. He continues biweekly treatments with minimal impact on daily activities, recently completing a three-week vacation to Hawaii. The treatment regimen has been well-tolerated, with the patient reporting that treatment breaks during vacations help clear chemotherapy (search) from his system, allowing him to feel "really good."
"He tolerates the treatment incredibly well, and he hasn't had any detriment to his quality of life," Leal confirmed.
Clinical Significance
This case demonstrates the potential for tucatinib combination therapy to significantly extend survival in metastatic esophageal cancer (search) patients while preserving quality of life. The sustained response over four years, with the patient remaining on first-line treatment, suggests this approach may offer substantial clinical benefits for HER2 (search)-positive esophageal cancers.
The patient's positive attitude and compliance with the intensive treatment schedule have contributed to his success, though the underlying therapeutic efficacy of the tucatinib combination appears to be the primary driver of his exceptional outcomes. His case has made him well-known among the infusion center staff, who celebrated his 100th treatment milestone with a signed card from the clinical and research teams.